Clarity AI Announces Partnership With Aspiration to Deliver Data-Led Climate and Impact Solutions for Consumer Platforms, as Consumer Demand for Sustainability Grows
26.7.2023 15:00:00 EEST | Business Wire | Press release
Clarity AI, the leading sustainability tech platform announces it has partnered with Aspiration, a top global climate finance company, to launch sustainability assessment solutions for consumer use cases. This unique partnership will deliver effective and accessible solutions to consumer platforms (e.g. e-commerce, retail banks, supermarkets, etc.) to help end users measure and reduce their carbon footprint and understand the sustainability performance of merchants by combining Clarity AI’s high-quality, transparent data and tools with Aspiration’s best-in-class carbon removal projects.
How the climate solution works
Customers will be able to assess the sustainability of the brands they buy and their current spending habits based on Clarity AI’s personalized data tracking and AI capabilities – helping them to identify ways to positively change their purchasing patterns.
Clarity AI’s technology will also provide sustainability insights at the individual retailer level. Leveraging its coverage of over 40,000 companies and more than 160 industries (the broadest in the market), Clarity AI calculates the impact of a consumer’s spending and helps them understand company-specific sustainability information rather than broad, industry-level spending trends. It also provides recommendations on how consumers can maximize the impact of their purchases and actions.
Based on this data, Aspiration will offer customers the opportunity to mitigate their carbon footprint by purchasing credits from high-quality, nature-based climate solutions that are rigorously vetted to deliver real, tangible impact that contributes toward the path to net zero.
Aspiration will also offer customers the opportunity to contribute to carbon removal projects with benefits beyond climate impact such as biodiversity improvements and job creation for underrepresented communities. This approach allows users to support projects that align with their values in broader environmental and social dimensions.
High customer demand for carbon data on purchases and mitigation strategies can be met with high-quality carbon credits
During a recent Clarity AI-hosted event for over 900 global brands (including Citigroup, eBay, and Target), companies revealed which sustainability metrics were most important to their customers.
Amongst the food and beverage, fashion, and electronics sectors – which accounted for 65% of responses – carbon emissions were the most critical metric, with 60% of respondents saying that their customers wanted to see this information. Additionally, 87% of attendees believed sustainability information about consumers’ purchases will be a must-have before 2030, with 44% of them believing it will be a must-have by 2025.
This consumer demand for quality sustainability information is increasing in line with the number of tools available to support sustainability projects, including carbon removals – between 2020 and 2021 the carbon market saw year-on-year growth of 164%.
However, rigorous quality control is critical to driving impact. Aspiration implements best-in-class standards when it comes to vetting carbon removal and avoidance projects – on average, less than one in five projects Aspiration reviews through its diligence process make it into its pipeline of approved projects.
This solution from Clarity AI and Aspiration aims to empower customers to understand the impact of their purchasing decisions and the opportunity for them to take effective action.
Rebeca Minguela, Founder & CEO of Clarity AI commented: “We believe that customers need and want to act, and they need data and tools to do so. They need to seamlessly see the carbon footprint of their purchases and trust that information. Then they need to easily offset those and get recommendations on how to maximize their impact going forward. Partnering with Aspiration, we can satisfy all those criteria and help consumers find a path to a more sustainable future.”
Olivia Albrecht, CEO of Aspiration commented: “The best way to transition to a low-carbon economy is for businesses, consumers, and communities to work collectively to achieve climate goals. The solution we're providing through our collaboration with Clarity AI is all about giving consumers access to climate data and the tools to take action right at their fingertips via their mobile apps.”
About Clarity AI
Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. Clarity AI’s capabilities are an essential tool for end-to-end sustainability analysis related to investing, corporate research, benchmarking, consumer e-commerce, and regulatory reporting. As of June 2023, Clarity AI’s platform analyzes more than 70,000 companies, 420,000 funds, 201 countries, and 199 local governments, which represents more breadth than any other player in the market. One way Clarity AI delivers on its mission to bring societal impact to markets is by ensuring its capabilities are delivered directly into clients' workflows through integrations with partners like BlackRock - Aladdin, Refinitiv an LSEG business, BNP Manaos, CACEIS, and SimCorp. Additionally, Clarity AI's sustainability insights reach more than 150 million consumers across more than 400,000 merchants. Clarity AI has offices in North America, Europe, and the Middle East, and its client network manages tens of trillions in assets and includes companies like Invesco, Nordea, BlackRock, Santander, Wellington, and BNP Paribas.
About Aspiration
Aspiration Partners is a high-impact climate finance company working at scale to help enterprises, consumers, and investors achieve their climate goals. Founded in 2013, the company sources, monitors, and invests in carbon removal projects across the globe to generate high-quality carbon credits. Every project in Aspiration's portfolio is held to the most rigorous standards, ensuring each drives tangible, positive impact for people and the planet. Aspiration is a certified B Corp, a member of Project Drawdown, 1t.org, Climate Pledge and many other critical industry groups dedicated to accelerating climate action. For more information, visit Aspiration.com or Aspiration.com/business.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230726278134/en/
Contact information
Media Contact
Edelman
clarityAI@edelmansmithfield.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
